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Bardoxolone methyl · eGFR
Abstract
Background: Increases in measured inulin clearance, mea-
sured creatinine clearance, and estimated glomerular filtra-
tion rate (eGFR) have been observed with bardoxolone 
methyl in 7 studies enrolling approximately 2,600 patients 
with type 2 diabetes (T2D) and chronic kidney disease 
(CKD). The largest of these studies was Bardoxolone Methyl 
Evaluation in Patients with Chronic Kidney Disease and 
Type 2 Diabetes (BEACON), a multinational, randomized, 
double-blind, placebo-controlled phase 3 trial which en-
rolled patients with T2D and CKD stage 4. The BEACON trial 
was terminated after preliminary analyses showed that pa-
tients randomized to bardoxolone methyl experienced sig-
nificantly higher rates of heart failure events. We performed 
post-hoc analyses to characterize changes in kidney func-
tion induced by bardoxolone methyl. Methods: Patients in 
 BEACON (n = 2,185) were randomized 1: 1 to receive once-
daily bardoxolone methyl (20 mg) or placebo. We com-
pared the effects of bardoxolone methyl and placebo on a 
post-hoc composite renal endpoint consisting of ≥30% de-
cline from baseline in eGFR, eGFR <15 mL/min/1.73 m2, and 
end-stage renal disease (ESRD) events (provision of dialysis 
or kidney transplantation). Results: Consistent with prior 
studies, patients randomized to bardoxolone methyl expe-
rienced mean increases in eGFR that were sustained through 
study week 48. Moreover, increases in eGFR from baseline 
were sustained 4 weeks after cessation of treatment. Pa-
tients randomized to bardoxolone methyl were significant-
ly less likely to experience the composite renal endpoint 
(hazards ratio 0.48 [95% CI 0.36–0.64]; p < 0.0001). Conclu-
sions: Bardoxolone methyl preserves kidney function and 
may delay the onset of ESRD in patients with T2D and stage 
4 CKD. © 2018 The Author(s) 
Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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Introduction
Through activation of Nrf2 (nuclear factor erythroid-
derived 2-related factor 2) and inhibition of NF-κB (nu-
clear factor kappa-light-chain-enhancer of activated B-
cells), bardoxolone methyl, a semi-synthetic triterpenoid, 
upregulates the antioxidant response and suppresses pro-
inflammatory signaling to reduce oxidative stress and in-
flammation and promote mitochondrial function [1, 2]. 
Bardoxolone methyl and close analogs demonstrate effi-
cacy in multiple rodent models of kidney disease, includ-
ing chronic kidney disease (CKD) induced by 5/6 ne-
phrectomy [3], cisplatin-induced acute nephrotoxicity 
[4, 5], angiotensin II-induced kidney injury [6], and pro-
tein overload-induced nephropathy [7]. Bardoxolone 
methyl has also been studied in 7 clinical trials enrolling 
approximately 2,600 patients with type 2 diabetes (T2D) 
and CKD. Improvements in glomerular filtration rate 
(GFR), assessed using measured inulin clearance, mea-
sured creatinine clearance, and estimated GFR (eGFR), 
have been observed with bardoxolone methyl treatment 
in a number of clinical trials [8–11]. The largest of these 
was a multinational, randomized, double-blind, placebo-
controlled phase 3 outcomes trial, which enrolled 2,185 
patients with T2D and CKD stage 4 (Bardoxolone Meth-
yl Evaluation in Patients with Chronic Kidney Disease 
and Type 2 Diabetes [BEACON]: The Occurrence of Re-
nal Events study) [10]. 
The BEACON trial was terminated for safety concerns 
in response to a recommendation from the independent 
data monitoring committee, which identified a signifi-
cant increase in the risk of heart failure hospitalizations 
or death from heart failure with bardoxolone methyl 
treatment (96 [8.8%] patients randomized to bardoxo-
lone methyl versus 55 [5.0%] patients randomized to pla-
cebo) [10]. After BEACON was terminated, analyses sug-
gested that the primary reason for the increase in adjudi-
cated heart failure related outcomes in the treatment 
group was not direct toxicity, but fluid overload, which 
occurred in the first 4 weeks after randomization [12]. 
Post-hoc analysis from BEACON identified 2 major risk 
factors as predictors of fluid overload events: elevated 
baseline B-type natriuretic peptide and prior hospitaliza-
tion for heart failure [13]. Patients without these risk fac-
tors showed no imbalance in heart failure events or mor-
tality, which is consistent with phase 1 and 2 clinical stud-
ies that primarily enrolled patients with CKD stage 3 who 
had better baseline kidney function and less cardiovascu-
lar disease [8, 14] than BEACON participants. Clinical 
development of bardoxolone methyl was restarted ex-
cluding at-risk patients by using these identified risk fac-
tors and closely monitoring trial participants for signs 
and symptoms of volume retention during the first few 
weeks after treatment initiation. Bardoxolone methyl is 
currently being tested in a global study in patients with 
CKD due to Alport syndrome (CARDINAL; 
NCT03019185), in patients with T2D and CKD in Japan 
(TSUBAKI; NCT02316821), a global phase 2 study of var-
ious pulmonary hypertension subtypes (LARIAT; 
NCT02036970), and a global phase 3 study of pulmonary 
arterial hypertension associated with connective tissue 
disease (CATALYST; NCT02657356). An interim analy-
sis from the TSUBAKI study demonstrated that bardoxo-
lone methyl increases GFR measured by inulin clearance 
after 16 weeks of study drug administration, without in-
creasing the risk for fluid overload [11]. Additional post-
hoc analyses of BEACON presented here were performed 




Previous publications describe the BEACON trial design [10, 
15]. Patients with T2D and CKD stage 4 were randomized 1: 1 to 
once-daily administration of bardoxolone methyl (20 mg) or pla-
cebo. The primary efficacy outcome of the study was the time-to-
first event in the composite outcome defined as end-stage renal 
disease (ESRD; need for chronic dialysis, renal transplantation, or 
renal death) or cardiovascular death. Secondary efficacy out-
comes included the change in eGFR, time-to-first hospitalization 
for heart failure or death due to heart failure, and time-to-first 
event of a composite consisting of non-fatal myocardial infarc-
tion, non-fatal stroke, hospitalization for heart failure, or cardio-
vascular death. An independent events adjudication committee 
(EAC), blinded to study treatment assignment, evaluated whether 
ESRD events, cardiovascular events, strokes, and fatalities met 
pre-specified definitions of primary and secondary endpoints, as 
described in the EAC charter [10]. Estimated GFR was calculated 
using serum creatinine and the Modification of Diet in Renal Dis-
ease study equation and assessed every 4 weeks through week 12, 
followed by assessments every 8 weeks thereafter. The study pro-
tocol was approved by Institutional Review Boards at participat-
ing study sites and was registered at ClinicalTrials.gov 
(NCT01351675). 
Statistical Methods
We performed longitudinal analyses of eGFR using mixed-ef-
fects regression with study group, time, the interaction of study 
group with time, eGFR at baseline, the interaction of baseline 
eGFR with time, and urinary albumin-to-creatinine ratio as co-
variates, and compared the mean changes in eGFR between the 
bardoxolone methyl and placebo groups.
We performed post-hoc time-to-event analyses for a compos-
ite renal endpoint consisting of 2 surrogate endpoints for kidney 
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failure, ≥30% decline from baseline in eGFR or eGFR values <15 
mL/min/1.73 m2 (for patients with baseline eGFR ≥15 mL/
min/1.73 m2), and adjudicated ESRD events in the intent-to-treat 
population in BEACON. Confirmation of each eGFR decline 
event was based on ≥30% decline from baseline in eGFR or eGFR 
<15 mL/min/1.73 m2 occurring at 2 or more visits. Hazards ratios 
and 95% CI were computed using Cox proportional hazards re-
gression models. Cases in which a patient had an eGFR value that 
declined ≥30% or fell below 15 mL/min/1.73 m2 at the last visit, 
but did not have a second confirmatory visit, were not considered 
events. Patients who did not experience one of these events were 
censored using the following conventions: patients who died 
from any cause prior to the end of the study were censored at the 
date of death; patients who discontinued the study prematurely, 
withdrew consent, or were lost to follow-up prior to the end of 
the study were censored at their last date of contact; patients who 
were alive and still being followed were censored on the study 
termination date. Similar analyses were also performed for a 
composite endpoint consisting of only the 2 surrogate endpoints 




A total of 2,185 were randomly assigned to receive bar-
doxolone methyl (n = 1,097) or placebo (n = 1,088). Previ-
ous publications detail the patient demographics and base-
line characteristics of the intention-to-treat population in 
BEACON [10, 16] (online suppl. Table 1; for all online sup-
pl. material, see www.karger.com/doi/10.1159/000486398). 
The demographics and baseline characteristics for the sub-
set of patients that remained on study through 48 weeks of 
treatment (bardoxolone methyl, n = 241; placebo, n = 281) 
were similar, but generally had lower baseline urine albu-
min-to-creatinine values relative to the overall intention-
to-treat population (online suppl. Table 1). The median 
duration of exposure to the study drug was 7 months 
(25th–75th percentile range: 3–11) among patients ran-
domly assigned to bardoxolone methyl and 8 months 
(25th–75th percentile range: 5–11) among those randomly 
assigned to placebo. 
Bardoxolone Methyl Increases eGFR 
As previously described, patients randomized to bar-
doxolone methyl had mean overall increases in eGFR of 
5.5 mL/min/1.73 m2 from a mean baseline eGFR of 22.4 ± 
4.3 mL/min/1.73 m2. In contrast, patients randomized to 
placebo arm had mean baseline eGFR values of 22.5 ± 4.6 
mL/min/1.73 m2 and experienced a mean decline in eGFR 
of –0.9 mL/min/1.73 m2 corresponding to a difference be-
tween groups of 6.4 mL/min/1.73 m2 (p < 0.001) [17]. 
The early improvements in eGFR with bardoxolone 
methyl were correlated with a sustained response and 
sustained eGFR increases; week 12 changes in eGFR were 
significantly correlated with changes from baseline in 
eGFR at week 48 (r = 0.48, p < 0.001; Fig. 1) and 4 weeks 
post-drug withdrawal (r = 0.43, p < 0.001; Fig. 1). More-
over, the increase in eGFR was highly consistent among 
patients, with over 75% of patients having some increase 
from baseline levels in eGFR at week 48 (Fig. 2). The mag-
nitude and proportion of patients with increases in eGFR 
from baseline >3 mL/min/1.73 m2 after 48 weeks of treat-
ment was also significantly higher (p < 0.001) in patients 
treated with bardoxolone methyl (147 out of 241 [61%]) 
versus placebo (41 out of 281 [15%]).
Increases in eGFR Associated with Reduced Loss of 
Kidney Function 
More than twice as many patients randomized to pla-
cebo experienced a composite kidney endpoint (147 vs. 
67 in patients randomized to bardoxolone methyl, haz-
ards ratio 0.48 [95% CI 0.36–0.64]; p < 0.0001; Fig. 3). For 
the composite that did not include adjudicated ESRD 
events, bardoxolone methyl decreased the proportion of 
patients with a confirmed 30% decline in eGFR or eGFR 
<15 mL/min/1.73 m2 by nearly 70% (n = 29 for bardoxo-
lone methyl versus, n  = 116 for placebo; hazards ratio: 
0.26 [95% CI 0.18–0.40]; p < 0.0001; Fig. 3). The individ-
ual components of the composite renal endpoint occur-
ring in patients randomized to bardoxolone methyl ver-
sus placebo are shown in online supplementary Table 2.
The number of patients who experienced a renal and 
urinary disorder serious adverse event (as defined by the 
Medical Dictionary for Regulatory Activities, MedDRA 
version 14.0) was numerically lower in the bardoxolone 
methyl group than in the placebo group (52 vs. 71, respec-
tively). Numerically fewer ESRD events were observed in 
the bardoxolone methyl group than in the placebo group 
(43 of 1,088 [4.0%] vs. 51 of 1,097 [4.6%], respectively) 
[17].
Bardoxolone Methyl Treatment Is Associated with a 
Sustained eGFR Increase after Withdrawal of Drug 
Patients also participated in a 4-week withdrawal pe-
riod following the last on-treatment visit. Based on the 
drug’s elimination half-life of approximately 40 h, sub-
therapeutic concentrations are achieved within approxi-
mately 10 days after drug withdrawal, and the 4-week 
withdrawal period represents approximately 17 half-lives 
of the drug. Moreover, there are no major metabolites 
with pharmacologic activity, so eGFR was assessed after 
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all pharmacologic activity from bardoxolone methyl ad-
ministration was lost. 
Four weeks after the last dose, the mean eGFR in pa-
tients randomized to bardoxolone methyl (n = 864) was 
24.4 ± 8.3 mL/min/1.73 m2, which was approximately 
9% higher than the mean baseline value of 22.4 ± 4.3 
mL/min/1.73 m2. The mean eGFR value in patients 
randomized to placebo (n = 896) 4 weeks after the with-
drawal period was 22.3 ± 6.9 mL/min/1.73 m2 com-


















































Placebo (n = 281)
Fig. 2. Distribution of changes from baseline in eGFR at week 48 in bardoxolone methyl-treated and placebo pa-
tients in BEACON. Bars represent eGFR changes from baseline at week 48 for individual patients. Data only in-
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Fig. 1. Early increases in eGFR with bardoxolone methyl correlate 
with durable response through 1 year and sustained eGFR benefit 
in BEACON. Scatter plots of (left) week 12 vs. 48 changes from 
baseline in eGFR and (right) changes from baseline in eGFR at 
week 12 vs. 4 weeks after last dose in bardoxolone methyl-treated 
patients. Data only include bardoxolone methyl patients treated 
for at least 48 weeks with eGFR data at week 12 and 48 (n = 236) 
or week 12 and 4 weeks post treatment (n = 221). Pearson correla-
tions were calculated using change from baseline in eGFR at week 
12 with changes at week 48 or post treatment.
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min/1.73 m2. Similarly, for patients that received at 
least 48 weeks of treatment (n = 273 for placebo and n = 
225 for bardoxolone methyl), approximately 20% of the 
on-treatment increase in eGFR was sustained following 
withdrawal of therapy (Table 1). The residual eGFR in-
crease from baseline observed in bardoxolone methyl-
treated patients (1.0 mL/min/1.73 m2), was significant-
ly different from the eGFR decline from baseline ob-


























































































Fig. 3. Time-to-event analysis for kidney failure composite out-
comes in BEACON. Kaplan-Meier plots of the time-to-first-event 
for composites consisting of: (top) ≥30% decline from baseline in 
eGFR, eGFR <15 mL/min/1.73 m2, and adjudicated ESRD events; 
(bottom) ≥30% decline from baseline in eGFR and eGFR <15 mL/
min/1.73 m2. Hazards ratios and 95% CI were computed using Cox 
proportional hazards regression models. Median duration of ex-
posure to the study drug was 7 months for patients randomized to 
bardoxolone methyl and 8 months for patients randomized to pla-
cebo.
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Discussion
Consistent with prior studies, patients treated with 
bardoxolone methyl in BEACON had mean increases in 
eGFR that occurred by week 4 of treatment. The early im-
provement in eGFR with bardoxolone methyl treatment 
translated to a sustained response as eGFR remained 
above baseline through week 48. The maintenance of 
eGFR increase for 1 year suggests that the effects may be 
durable, and patients do not develop tolerance to the 
drug. 
In preclinical studies, bardoxolone methyl has been 
shown to increase GFR by increasing glomerular surface 
area through reduction of endothelial dysfunction, an-
giotensin II-induced mesangial cell contraction, and 
whole glomerular contraction [6, 18, 19], and the im-
provements in eGFR that are evident within the first 
4 weeks of bardoxolone methyl treatment in BEACON 
are likely due to the reversal of these dynamic inflamma-
tion-mediated processes. Moreover, the presence of a sus-
tained eGFR improvement after withdrawal of drug sug-
gest that the maladaptive structural deficits that contrib-
ute to declining kidney function (such as expansion of the 
mesangium and interstitial fibrosis) may be improved 
over the course of longer term treatment with bardoxo-
lone methyl. 
The prevailing hypothesis for GFR decline in the 
model of CKD is that hyperfiltration accelerates glomer-
ular damage. Based on data from preclinical studies as 
well as clinical studies such as African American Study 
of Kidney Disease, a study of blood pressure targets (i.e., 
mean arterial pressure of ≤92 mm Hg in the intensive 
control group and 102–107 mm Hg in the standard con-
trol group) and specific blood pressure lowering agents 
(i.e., ramipril, metoprolol, and amlodipine) in hyperten-
sive kidney disease, it has been widely believed that in-
terventions that result in higher GFR in the short term 
are damaging. Agents that increase eGFR through in-
creases in intraglomerular pressure would be expected 
to cause a decline in kidney function relative to placebo 
due to pressure-mediated injury; in African American 
Study of Kidney Disease, patients with who received am-
lodipine had accelerated rates of eGFR decline after 
6  months of treatment compared to those receiving 
ramipril or metoprolol [20]. Here, we show that patients 
treated with bardoxolone experience a sustained in-
crease in eGFR over time and a sizeable fraction of that 
increase is sustained 4 weeks after the drug has been 
withdrawn, long after active concentrations of the drug 
are evident. These results are consistent with data from 
a separate 52-week phase 2 study in patients with T2D 
and stage 3b/4 CKD. In that study, patients treated with 
bardoxolone methyl at doses similar to that studied in 
BEACON also showed significant increases in eGFR rel-
ative to baseline and placebo 4 weeks after withdrawal of 
treatment (4.1 ± 1.4 for bardoxolone methyl-treated pa-
tients versus –0.7 ± 1.1 for placebo-treated patients) [8]. 
Also consistent with the hypothesis that the observed 
increases in eGFR with bardoxolone methyl treatment 
are not harmful was the lack of increases in other mark-
ers of kidney injury (urinary neutrophil gelatinase-asso-
ciated lipocalin and N-acetyl-beta-d-glucosaminidase) 
[14]. 
In animals, a bardoxolone methyl analog prevents fi-
brosis, preserves kidney function, and slows CKD pro-
gression in the 5/6 nephrectomy model of hyperfiltra-
tion-induced chronic kidney failure [3]. It is not known 
whether similar structural effects occur in humans; how-
ever, the aforementioned withdrawal data with bardoxo-
lone methyl may be indicative of disease-modifying re-
modeling that leads to partially sustained benefit after 
cessation of study drug. 
The BEACON trial was terminated after accrual of 
only approximately one-third of the planned events. As 
such, too few ESRD events occurred to reliably determine 
the drug’s true effect on delaying the risk for development 
Table 1. Mean eGFR change from baseline at end of treatment and 4 weeks post withdrawal in BEACON
Mean eGFR change from baseline ± SEM
na end of treatment 4 weeks post-withdrawal
Placebo 273 –1.2±0.3 –0.8±0.3
Bardoxolone methyl 225 5.7±0.6b 1.0±0.5b
a Number of patients receiving at least 48 weeks of treatment with 4-week post-withdrawal data. 
b p < 0.001 vs. placebo.
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of kidney failure. Nevertheless, bardoxolone methyl treat-
ment resulted in a decreased number of adverse kidney 
outcomes in BEACON, as assessed by kidney-related se-
rious adverse events and ESRD events. Bardoxolone 
methyl also significantly decreased the likelihood of a 
composite renal endpoint consisting of adjudicated ESRD 
along with 2 endpoints that have recently been estab-
lished as valid surrogates for progression to kidney failure 
in clinical trials of CKD [20, 21], ≥30% decline in eGFR 
and eGFR <15 mL/min/1.73 m2, as well as adjudicated 
ESRD events in BEACON. 
Bardoxolone methyl has been associated with signifi-
cant decreases in weight [22], which could, in theory, con-
tribute to the observed increases in eGFR. However, in a 
Japanese study, bardoxolone methyl significantly in-
creased measured GFR, as assessed by inulin clearance, in 
stage 3 CKD patients after 16 weeks of treatment com-
pared to placebo [11], demonstrating that bardoxolone 
methyl-mediated eGFR increases are reflective of true 
improvements in measured GFR. Bardoxolone methyl 
also significantly increases creatinine clearance [10, 14], 
and these increases were not associated with a change in 
total 24-h excretion of creatinine [14], establishing that 
the increase in creatinine clearance is not due to a change 
in creatinine metabolism. Furthermore, in BEACON and 
prior CKD studies, bardoxolone methyl significantly re-
duced other retained solutes (i.e., blood urea nitrogen, 
uric acid, and phosphate) in inverse correlation to eGFR 
increases [8, 10], supporting that the increases in eGFR 
are associated with improvements in other measures of 
kidney function. 
Although the BEACON study was terminated due to 
an increase in heart failure hospitalizations in the bar-
doxolone methyl treated group, the increase in heart fail-
ure events appeared to be due to fluid overload that oc-
curred in patients with 2 major risk factors: elevated 
baseline B-type natriuretic peptide and prior hospital-
ization for heart failure [13]. The clinical phenotype of 
fluid overload and heart failure in BEACON was similar 
to that observed with endothelin receptor antagonists in 
advanced CKD patients [23], and additional post-hoc 
analyses suggest that through modulation of the endo-
thelin pathway, bardoxolone methyl may pharmacolog-
ically promote acute sodium and volume retention and 
increase blood pressure in patients with more advanced 
CKD [12]. Exclusion of at-risk patients, including those 
with late-stage CKD, and additional risk mitigation fea-
tures have been implemented in clinical programs with 
bardoxolone methyl and a related analog, omaveloxo-
lone, including 7 studies that enrolled approximately 
400 patients, which have not shown increased risk for 
fluid overload to date. Studies are continuing, in patients 
without identified risk factors for fluid overload, to fur-
ther evaluate the potential risk-benefit profile for bar-
doxolone methyl and determine whether the increases in 
eGFR and with bardoxolone methyl offer the potential 
to prevent or delay kidney function decline and progres-
sion to ESRD. Bardoxolone methyl is currently being 
tested in a global study in patients with CKD due to Al-
port syndrome (CARDINAL; NCT03019185) and in pa-
tients with T2D and CKD in Japan (TSUBAKI; 
NCT02316821).
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